CCRL2 and acute myeloid leukemia: Next, to compare the efficacy of ADC targeting CCRL2 with the efficacy of ADCs against other targets, PBD-conjugated ADCs targeting the well described AML targets CD33, and CD123 were developed (Supplementary Figs. 1E-F).